2026.10.26
Tillotts strengthens pharmaceutical manufacturing base with planned acquisition in Gronau
RHEINFELDEN, Switzerland, 26 October 2026 – Tillotts Pharma AG (Tillotts) signed an agreement on 23 October 2026 to acquire Haupt Pharma Wülfing GmbH (HPW), based in Gronau, Germany. With this acquisition, Tillotts is expanding its pharmaceutical production capacities and strengthening its own value creation. The parties have agreed not to disclose the purchase price. The acquisition is subject to the conditions customary for such a transaction, including the granting of the necessary regulatory approvals.
The Gronau site has been a key manufacturer of Asacol®, a core product in the Tillotts portfolio, for many years. The acquisition will enable Tillotts to directly manage production capacity, planning and quality in future, and to flexibly tailor production to market requirements.
“Reliability is essential to us. Patients and our partners rely on us to supply them safely with high-quality products. With the Gronau site, we are strengthening our ability to live up to that trust over the long term,” says Thomas A. Tóth von Kiskér, CEO of the Tillotts Group.
Tillotts plans to invest around EUR 23 million in the Gronau site over the coming years. This investment is intended to modernise the site, further improve quality and efficiency, and lay the foundations for future growth.
The acquisition forms part of Tillotts’ long-term strategy as a growing specialty pharmaceutical company with high-performance manufacturing sites. It is intended to support the long-term supply of the existing portfolio, which is currently marketed in around 65 countries.
An established site with valuable expertise
The Gronau site has a pharmaceutical history spanning more than 100 years. Its capabilities include the development, manufacture and packaging of solid dosage forms; analytical and formulation services; and the packaging and distribution of clinical trial supplies.
Once the takeover is complete, around 280 employees will become part of the Tillotts Group, which already employs 370 people across Europe. The specialist knowledge and many years of experience of the staff at the Gronau site are key to maintaining and further developing the site’s expertise in a targeted manner.
“The strength of this site lies in its people and their expertise. We look forward to welcoming the employees to Tillotts and building on this experience together,” says Thomas A. Tóth von Kiskér, CEO of the Tillotts Group.
Media enquiries:
Tillotts Pharma AG
Susi Teichmann
Corporate Communications Lead
Phone: +41 79 692 27 96
Email: susi.teichmann@tillotts.com
About Tillotts
Tillotts Pharma AG, part of the Japanese Zeria Group, is a fast-growing specialty pharmaceutical company with 370 employees in Switzerland and abroad. Tillotts is dedicated to the development, acquisition and commercialisation of innovative pharmaceutical products for the digestive system. Tillotts successfully markets its own products for the treatment of inflammatory bowel disease (IBD) and Clostridioides difficile infection (CDI), as well as in-licensed products, in around 65 countries through its European subsidiaries and a global network of partners.
All trademarks used or mentioned in this press release are legally protected.
Copyright © Tillotts Pharma AG. All rights reserved.
For more information, please visit www.tillotts.com.
About Zeria
Zeria Pharmaceutical Co., Ltd., founded in 1955 and headquartered in Tokyo, Japan, focuses on the research and development, manufacture and sale of prescription medicines and over-the-counter (OTC) products. The company is listed on the Prime Market of the Tokyo Stock Exchange (stock code: 4559). Zeria holds a leading position in gastroenterology in Japan and operates internationally through various subsidiaries. For more information about Zeria, please visit www.zeria.co.jp.
object(WP_Post)#17008 (24) {
["ID"]=>
int(8937)
["post_author"]=>
string(4) "1207"
["post_date"]=>
string(19) "2026-10-26 11:16:40"
["post_date_gmt"]=>
string(19) "2026-10-26 10:16:40"
["post_content"]=>
string(7128) "
RHEINFELDEN, Switzerland, 26 October 2026 – Tillotts Pharma AG (Tillotts) signed an agreement on 23 October 2026 to acquire Haupt Pharma Wülfing GmbH (HPW), based in Gronau, Germany. With this acquisition, Tillotts is expanding its pharmaceutical production capacities and strengthening its own value creation. The parties have agreed not to disclose the purchase price. The acquisition is subject to the conditions customary for such a transaction, including the granting of the necessary regulatory approvals.
The Gronau site has been a key manufacturer of Asacol®, a core product in the Tillotts portfolio, for many years. The acquisition will enable Tillotts to directly manage production capacity, planning and quality in future, and to flexibly tailor production to market requirements.
“Reliability is essential to us. Patients and our partners rely on us to supply them safely with high-quality products. With the Gronau site, we are strengthening our ability to live up to that trust over the long term,” says Thomas A. Tóth von Kiskér, CEO of the Tillotts Group.
Tillotts plans to invest around EUR 23 million in the Gronau site over the coming years. This investment is intended to modernise the site, further improve quality and efficiency, and lay the foundations for future growth.
The acquisition forms part of Tillotts’ long-term strategy as a growing specialty pharmaceutical company with high-performance manufacturing sites. It is intended to support the long-term supply of the existing portfolio, which is currently marketed in around 65 countries.
An established site with valuable expertise
The Gronau site has a pharmaceutical history spanning more than 100 years. Its capabilities include the development, manufacture and packaging of solid dosage forms; analytical and formulation services; and the packaging and distribution of clinical trial supplies.
Once the takeover is complete, around 280 employees will become part of the Tillotts Group, which already employs 370 people across Europe. The specialist knowledge and many years of experience of the staff at the Gronau site are key to maintaining and further developing the site’s expertise in a targeted manner.
“The strength of this site lies in its people and their expertise. We look forward to welcoming the employees to Tillotts and building on this experience together,” says Thomas A. Tóth von Kiskér, CEO of the Tillotts Group.
Media enquiries:
Tillotts Pharma AG
Susi Teichmann
Corporate Communications Lead
Phone: +41 79 692 27 96
Email: susi.teichmann@tillotts.com
About Tillotts
Tillotts Pharma AG, part of the Japanese Zeria Group, is a fast-growing specialty pharmaceutical company with 370 employees in Switzerland and abroad. Tillotts is dedicated to the development, acquisition and commercialisation of innovative pharmaceutical products for the digestive system. Tillotts successfully markets its own products for the treatment of inflammatory bowel disease (IBD) and Clostridioides difficile infection (CDI), as well as in-licensed products, in around 65 countries through its European subsidiaries and a global network of partners.
All trademarks used or mentioned in this press release are legally protected.
Copyright © Tillotts Pharma AG. All rights reserved.
For more information, please visit www.tillotts.com.
About Zeria
Zeria Pharmaceutical Co., Ltd., founded in 1955 and headquartered in Tokyo, Japan, focuses on the research and development, manufacture and sale of prescription medicines and over-the-counter (OTC) products. The company is listed on the Prime Market of the Tokyo Stock Exchange (stock code: 4559). Zeria holds a leading position in gastroenterology in Japan and operates internationally through various subsidiaries. For more information about Zeria, please visit www.zeria.co.jp."
["post_title"]=>
string(89) "Tillotts strengthens pharmaceutical manufacturing base with planned acquisition in Gronau"
["post_excerpt"]=>
string(0) ""
["post_status"]=>
string(7) "publish"
["comment_status"]=>
string(6) "closed"
["ping_status"]=>
string(6) "closed"
["post_password"]=>
string(0) ""
["post_name"]=>
string(22) "tillotts-pharma-gronau"
["to_ping"]=>
string(0) ""
["pinged"]=>
string(0) ""
["post_modified"]=>
string(19) "2026-10-26 14:22:34"
["post_modified_gmt"]=>
string(19) "2026-10-26 13:22:34"
["post_content_filtered"]=>
string(0) ""
["post_parent"]=>
int(0)
["guid"]=>
string(52) "https://www.tillotts.com/?post_type=news&p=8937"
["menu_order"]=>
int(0)
["post_type"]=>
string(4) "news"
["post_mime_type"]=>
string(0) ""
["comment_count"]=>
string(1) "0"
["filter"]=>
string(3) "raw"
}